• Collaboration Includes BCMA CAR Constructs with Fully-Human Binding Domains
• Potential to Accelerate Juno’s Multiple Myeloma Program

Seattle, WA, New York, NY, and Emeryville, CA (Press Release) – Juno Thera­peutics, Inc. (Nasdaq: JUNO), a bio­pharma­ceu­tical com­pany focused on re-engaging the body's immune sys­tem to revolutionize the treat­ment of cancer, announced today that it has entered into an exclusive license agree­ment with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Thera­peutics, Inc. for a novel, fully-human binding domain targeting B-cell maturation an­ti­gen (BCMA), along with binding domains against two addi­tional undisclosed multiple myeloma targets to be used for the poten­tial devel­op­ment and com­mer­cial­iza­tion of chi­meric an­ti­gen re­cep­tor (CAR) cell ther­a­pies for patients with multiple myeloma. The binding domains were devel­oped under a col­lab­o­ration agree­ment be­tween Eureka Thera­peutics and MSK. The parties ex­pec­t the BCMA CAR to enter human testing as early as 1H2017.

“We are op­ti­mis­tic that CAR T ther­apy can be an im­por­tant component in treating patients with multiple myeloma, and we are pleased to bring addi­tional fully-human binding domains against BCMA and other targets into our pro­gram,” said Hy Levitsky, M.D., Juno’s Chief Scientific Officer. “We believe that a multi-pronged ap­proach may be nec­es­sary to treat this dis­ease, and we will pursue more than one target against myeloma. The MSK and Eureka con­structs are promising addi­tions to our port­folio that will accelerate our efforts and provide addi­tional oppor­tu­ni­ties to combat this dis­ease.”

"We are pleased to work with Juno Thera­peutics on devel­op­ing CAR T ther­a­pies against multiple myeloma," said Dr. Cheng Liu, Pres­i­dent and Chief Executive Officer of Eureka Thera­peutics. “Multiple myeloma is a dev­as­tat­ing dis­ease. For the past three years, we have been work­ing with MSK to develop CAR T ther­a­pies against multiple myeloma, and we are delighted that Juno is able to use their broad ex­per­tise to bring these ther­a­pies to patients faster."

MSK and Eureka Thera­peutics are eli­gible to receive an undisclosed up­front pay­ment, addi­tional pay­ments upon the achieve­ment of undisclosed clin­i­cal, regu­la­tory, and commercial mile­stones, and royalties on net sales.

About Eureka Thera­peutics, Inc.

Eureka Thera­peutics Inc. is a privately held bio­technology com­pany, headquartered in the San Francisco Bay area, focused on devel­op­ing first-in-class T cell immuno­therapies for hema­to­logical malig­nan­cies and solid tumors. Its core tech­nology plat­forms center around the discovery and engi­neer­ing of fully human anti­bodies against intracellular targets via the MHCI complex. The com­pany is devel­op­ing a pipe­line of novel cancer thera­peutics targeting intracellular oncogenes.

www.eurekainc.com

About Memorial Sloan Kettering

Memorial Sloan Kettering Cancer Center is the world’s oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Its scientists and clinicians generate inno­va­tive ap­proaches to better under­stand, diagnose, and treat cancer. Memorial Sloan Kettering specialists are leaders in biomedical research and in translating the latest research to ad­vance the standard of cancer care world­wide.

www.mskcc.org

About Juno

Juno Thera­peutics is build­ing a fully integrated bio­pharma­ceu­tical com­pany focused on re-engaging the body’s immune sys­tem to revolutionize the treat­ment of cancer. Founded on the vision that the use of human cells as thera­peutic entities will drive one of the next im­por­tant phases in med­i­cine, Juno is devel­op­ing cell-based cancer immuno­therapies based on chi­meric an­ti­gen re­cep­tor and high-affinity T cell re­cep­tor tech­nolo­gies to genetically engi­neer T cells to recog­nize and kill cancer. Juno is devel­op­ing multiple cell-based prod­uct can­di­dates to treat a variety of B-cell malig­nan­cies as well as solid tumors. Several prod­uct can­di­dates have shown compelling clin­i­cal responses in clin­i­cal trials in refractory leukemia and lym­phoma conducted to date. Juno's long-term aim is to im­prove and leverage its cell-based plat­form to develop new prod­uct can­di­dates that address a broader range of cancers and human dis­eases. Juno brings together inno­va­tive tech­nolo­gies from some of the world's leading research institutions, in­clud­ing the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, the University of California, San Francisco, and The National Cancer Institute. Juno Thera­peutics has an exclusive license to the St. Jude Children’s Research Hospital patented tech­nology for CD19 directed prod­uct can­di­dates that use 4-1BB, which was devel­oped by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital.

Juno Forward-Looking Statements

This press release con­tains “forward-looking state­ments” within the meaning of the Private Se­cu­ri­ties Lit­i­ga­tion Reform Act of 1995, Section 27A of the Se­cu­ri­ties Act of 1933, and Section 21E of the Se­cu­ri­ties Exchange Act of 1934, in­clud­ing state­ments re­gard­ing Juno’s business plans, the poten­tial of T cell thera­peutics, the poten­tial of the BCMA binding domain and other human binders, clin­i­cal trial results and clin­i­cal trial plans, and planned activities and poten­tial pay­ments under the license agree­ment among Juno, Memorial Sloan Kettering, and Eureka Thera­peutics. Forward-looking state­ments are subject to risks and un­cer­tainties that could cause actual results to differ ma­teri­ally from such for­ward-looking state­ments, and reported results should not be con­sidered as an indi­ca­tion of future per­for­mance. These risks and un­cer­tainties in­clude, but are not limited to, risks asso­ci­ated with: the success, cost, and timing of Juno's prod­uct devel­op­ment activities and clin­i­cal trials; Juno's ability to obtain regu­la­tory approval for and to com­mer­cial­ize its prod­uct can­di­dates; Juno's ability to estab­lish­ a commercially-viable manu­fac­tur­ing process and manu­fac­tur­ing infrastructure; regu­la­tory requirements and regu­la­tory devel­op­ments; success of Juno's com­pet­i­tors with respect to com­pet­ing treat­ments and tech­nolo­gies; Juno's dependence on third-party col­lab­o­rators and other contractors in Juno's research and devel­op­ment activities, in­clud­ing for the conduct of clin­i­cal trials and the manu­fac­ture of Juno's prod­uct can­di­dates; Juno's dependence on Celgene for the devel­op­ment and com­mer­cial­iza­tion outside of North America and China of Juno’s CD19 prod­uct can­di­dates and any other prod­uct can­di­dates for which Celgene exercises an option; Juno’s dependence on JW Thera­peutics (Shanghai) Co., Ltd, over which Juno does not exercise com­plete control, for the devel­op­ment and com­mer­cial­iza­tion of prod­uct can­di­dates in China; Juno's ability to obtain, main­tain, or protect intellectual property rights related to its prod­uct can­di­dates; amongst others. For a further description of the risks and un­cer­tainties that could cause actual results to differ from those ex­pressed in these for­ward-looking state­ments, as well as risks relating to Juno's business in general, see Juno's Annual Report on Form 10-Q filed with the Se­cu­ri­ties and Exchange Com­mis­sion on May 10, 2016 and Juno’s other periodic reports filed with the Se­cu­ri­ties and Exchange Com­mis­sion. These for­ward-looking state­ments speak only as of the date hereof. Juno disclaims any obli­ga­tion to update these for­ward-looking state­ments.

Source: Juno.